CYTORI THERAPEUTICS INC. overview

AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences. Event H.C. Wainwright BioConnect Conference Date January 11-14, 2021 Time Presentation available on demand January 11-14, 2021 Event Biotech Showcase 2021...

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The sixth cohort of the...

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13 th Annual LD Micro Main Event Conference on Monday, December 14 th at 10:40 a.m. ET. For conference participants, a live webcast of the...

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center,...

Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy RNL was g enerally well- t olerated w ith n o d ose- l imiting t oxicities o bserved Company m anagement and p rincipal i nvestigator of ReSPECT to d iscuss i nterim d ata d uring w ebinar s cheduled for Thursday , November 19 , 20 20 at 4 :30 - 5:30 p.m. ET AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV...

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Company management has been invited to participate in two upcoming virtual investor conferences: Event Virtual Fall Investor Summit Date November 17, 2020 Presentation Time 3:00 p.m. ET Event A.G.P. Virtual Healthcare Symposium Date November 19, 2020 Investors interested in arranging a...

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data Webinar Scheduled for Thursday, November 19, 2020 at 4:30 - 5:30 p.m. ET AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, personalized and targeted therapies for rare and difficult to treat cancers, today announced it will host a webinar on Thursday, November 19, 2020, 4:30 to 5:30 p.m. ET. The call...

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of leading experts in the fields of neuro-oncology, preclinical drug development, and nanotechnology. The SAB will guide and advise the Company as it advances its proprietary and versatile nanotechnology platform...